Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Jul 2024 – Nov 2025Where it's discussed
-
News377 articles
-
X / Twitter271 posts
-
Blogs18 articles
-
Bluesky10 posts
-
YouTube10 videos
-
Reddit4 posts
-
Facebook2 posts
AI synopsis
What people are saying
Overall, the discussions demonstrate strong agreement on the potential risks of NAION associated with semaglutide, with participants citing recent studies, such as Hathaway's 2024 report, and expressing concern about vision loss, highlighting the serious implications of these findings. The tone combines caution and scientific curiosity, emphasizing the need for further investigation and awareness among healthcare providers and patients.
Most discussions acknowledge the potential link between semaglutide and NAION, reflecting consensus or cautious concern about the findings.
Participants show high curiosity and concern, evidenced by mentions of studies, clinical implications, and requests for expert opinions.
Comments delve into detailed analysis, referencing multiple studies, sharing personal opinions and calling for further research, indicating deep involvement.
This topic appears to significantly influence current medical discussions, patient safety considerations, and regulatory scrutiny regarding semaglutide's risks.
Top posts
Most liked on X and BlueskySource: https://t.co/HCO6Ukmoek
Am Ende ist man schlank, aber leider blind? Semaglutid steht im Verdacht, das Risiko für die nicht arteriitische anteriore ischämische Optikus-Neuropathie (NAION) zu erhöhen, je nach Studie um das bis 4-fache. https://t.co/7Ykc3fmO5v https://t.co/eaMgUlZ2ky
STUDY: Ozempic tied to rare blinding condition Patients prescribed Ozempic or Wegovy for diabetes or weight loss had a higher risk of having a potentially blinding eye condition called NAION than similar patients not on the drugs. https://t.co/PqhNnIOQ2i https://t.co/1GaZAFfIO0 https://t.co/uzTTuQTHMS
GLP-1受容体作動薬Semaglutideと非動脈炎性前部虚血性視神経症NAIONのリスクに関する論文 @JAMAOphth (2024) 因果関係はわかりませんが注視したいですね。 Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/uzXEYHr0aG
If you are taking Glp1a for wt loss then be sure you have a good health insurance policy with you. You may need it h/t @arunkumar3112 @dlifein @TheIraSahay
All mentions
Risks Associated with Semaglutide and Tirzepatide for Weight Loss
This video discusses the risks and side effects of weight loss medications, particularly semaglutide and tirzepatide. It emphasizes the importance of safe and moderate use, referencing UK and American guidelines, while…
Semaglutide and Rare Blindness Risk: What You Need to Know
This video discusses the recent study linking semaglutide, used for diabetes and obesity, to a rare form of blindness called Nonarteritic Anterior Ischemic Optic Neuropathy. Learn about the potential risks and…
Semaglutide and Risk of Optic Neuropathy in Diabetes Patients
This video explores a study published in JAMA Ophthalmology on the potential connection between semaglutide, used for type 2 diabetes and weight loss, and the risk of nonarteritic anterior ischemic optic neuropathy.
Semaglutide and Vision Risks: Understanding Rare Eye Side Effects
Ozempic, Wegovy, and Rybelsus are medications for type 2 diabetes management. This video explains how semaglutide can cause vision issues, including rare risks like NAION and potential worsening of diabetic retinopathy…
Semaglutide Linked to Vision Loss: Risks and Insights
Research investigates the potential risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed Semaglutide, highlighting important safety considerations for users of this diabetes medication.
Evaluating the Risk of Optic Neuropathy in Semaglutide Patients
Interview with Dr. Joseph F Rizzo III discussing the potential link between Semaglutide and nonarteritic anterior ischemic optic neuropathy, highlighting recent research and clinical considerations.
Medical Alert: Ozempic and Risk of Permanent Blindness
Recent study in JAMA Ophthalmology links semaglutide, used in Ozempic and Wegovy, to increased risk of nonarteritic anterior ischemic optic neuropathy. Patients on semaglutide have six times higher risk of developing…
Adverse Effects of Semaglutide Including Optic Neuropathy Risks
This video discusses the safety profile of Semaglutide, highlighting potential adverse effects such as nonarteritic anterior ischemic optic neuropathy, based on recent clinical research and expert analysis.
Scientific Insights on Weight Loss Supplements and Eye Health Risks
Weight loss supplements may have side effects. This video discusses scientific findings on potential risks, including eye health issues, and emphasizes consulting healthcare professionals for safe treatment decisions…
Ozempic and Vision Loss: An Evidence-Based Review
Recent headlines suggest medications like Ozempic may cause blindness. This video explains the science behind these claims, including studies from Denmark, Harvard, and the US, highlighting the actual risks versus…
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA Ophthalmology | JAMA Network https://t.co/YjAkybvY4f
@IPostAndGhost What's more expensive? Being fat or being blind? Once again, I'm nervous about the consequences of the second & third order. https://t.co/pCFW1we5ye
@figurative1yLit @SamanthaJBryan1 @TheLaurenChen It is. And the condition is irreversible. Robby Williams not only is losing eye sight because of the injections but also developed scurvy, a condition we thought would be long gone. https://t.co/m8fUxbCWsB
RT @EricTopol: First report of an association of a GLP-1 drug (semaglutide) and risk of NAION, a form of optic neuropathy (2nd most common…
@prabhavkashyapg @ku1deep This is the alternative with serious side effects for what could be achieved by cultivating self discipline https://t.co/iKCZJNMLFB
@NathalieAgape @ImBreckWorsham https://t.co/7Xb4AnUgJZ
@MdBreathe They are linked to neuropathy: https://t.co/45tqee1r7t
@MAHA_Action I guess you want more Americans to go blind. https://t.co/45tqee1r7t
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA Ophthalmology | JAMA Network https://t.co/YjAkybvY4f
@FridoKala Already being looked at over semaglutide weight loss drugs, more studies are needed before declaring it down to the drug itself, but it's a potential issue https://t.co/Sdge1EHwmX
RT @ehlJAMA: DO GLP-1 Agonists Really Cause Eye Disease There has been a huge amount of press about a report showing an association betwee…
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy with Semaglutide; Diabetic Retinopathy; cumulative incidence of NAION for semaglutide & non–GLP-1 RA cohorts over 36mth was 8.9% and 1.8%.⬆️risk of NAION receiving semaglutide ([HR], 4.28; P < .001). https://t.co/I29btRKcou
RT @JAMAOphth:
RT @JAMAOphth:
RT @JAMAOphth:
RT @JAMAOphth:
RT @JAMAOphth:
RT @JAMAOphth:
RT @JAMAOphth:
RT @JAMAOphth:
RT @JAMAOphth:
https://t.co/NG9Ra15VqU
RT @JAMAOphth: Most viewed this week from @JAMAophth: #Semaglutide, taken for diabetes or obesity, was associated with non-arteritic anter…
Most viewed this week from @JAMAophth: #Semaglutide, taken for diabetes or obesity, was associated with non-arteritic anterior ischemic optic neuropathy (NAION). https://t.co/5yUPUoCobQ https://t.co/IOY8Lm4SxH
RT @JAMAOphth: Most viewed this week from @JAMAophth: #Semaglutide, taken for diabetes or obesity, was associated with non-arteritic anter…
RT @JAMAOphth: Most viewed this week from @JAMAophth: #Semaglutide, taken for diabetes or obesity, was associated with non-arteritic anter…
Most viewed this week from @JAMAophth: #Semaglutide, taken for diabetes or obesity, was associated with non-arteritic anterior ischemic optic neuropathy (NAION). https://t.co/eDKUG1n6Ku https://t.co/7HipGLd2zD
3. Two types of vision indications NAION— maybe real, maybe not, frequency in the 1/10,000 range. https://t.co/KhMFsdLwWC https://t.co/KwpFmy6mD6 https://t.co/KLArnWYG9C
@cabrn22761720 Dureza isso, né? Separei este dois estudos para ele ler
@MinorityFinge @FringedCanuck You are refering to his .. https://t.co/D9Ik8dmPY5 and you don't know what you are talking about.
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/66SA0GMvtp
RT @kym83810679: @drkeithsiau https://t.co/YdoPCi8ar4 https://t.co/FH8iNfzlf7 https://t.co/dPOViAMcsL
@AnitaPadilla32 @DavidWolfe https://t.co/d4bKDNinr6
RT @JAMAOphth: Most viewed this week from @JAMAophth: #Semaglutide, taken for diabetes or obesity, was associated with non-arteritic ante…
RT @kym83810679: @drkeithsiau https://t.co/YdoPCi8ar4 https://t.co/FH8iNfzlf7 https://t.co/dPOViAMcsL
@drkeithsiau https://t.co/YdoPCi8ar4 https://t.co/FH8iNfzlf7 https://t.co/dPOViAMcsL
RT @JAMAOphth: Most viewed this week from @JAMAophth: #Semaglutide, taken for diabetes or obesity, was associated with non-arteritic ante…
Most viewed this week from @JAMAophth: #Semaglutide, taken for diabetes or obesity, was associated with non-arteritic anterior ischemic optic neuropathy (NAION). https://t.co/IGNOcqc8hx https://t.co/p7tJAmQDT5
RT @JAMAOphth: Most viewed this week from @JAMAophth: #Semaglutide, taken for diabetes or obesity, was associated with non-arteritic ante…
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
Most viewed this week from @JAMAophth: #Semaglutide, taken for diabetes or obesity, was associated with non-arteritic anterior ischemic optic neuropathy (NAION). https://t.co/KWoNXEbzO5 https://t.co/g23k6m5rhQ
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
@HughEdw54983916 @grok @wonderful1s @aaronnpearsall https://t.co/FH8iNfzlf7 https://t.co/QEvuLYWa82 https://t.co/dPOViAMcsL
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
https://t.co/VjYkcY4vRz
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
Looking around for more sources but it sure seems like: 1. This adds 1 per 10k person-years risk of NAION 2. This increases 8.9% (diabetes) risk of NAION (or 7,64% for obesity). Coming from the EU (tighter regs) and US #ozempic https://t.co/EW2UOja6n5 https://t.co/PZI6L1dvR6
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
RT @MdBreathe: Source: https://t.co/HCO6Ukmoek
Source: https://t.co/HCO6Ukmoek
Recently, there have been several reports suggesting that the use of once-weekly semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is associated with an increased risk of NAION. https://t.co/UJx5GTmSmx
Ooooooh boy. https://t.co/ojW14Er52s https://t.co/Mfx6oz72d7
@IronSage_ https://t.co/rGJfq8RY6K
In type 2 #diabetes patients with no prior eye disorders, #semaglutide or #tirzepatide treatment increased the risk of nonarteritic anterior ischemic optic neuropathy and other optic nerve disorders. ja.ma/4llIYJe
Most viewed this week from @JAMAophth: #Semaglutide, taken for diabetes or obesity, was associated with non-arteritic anterior ischemic optic neuropathy (NAION). https://t.co/K4W8gc8skN https://t.co/tWiaMDWrqh
Most viewed this week from @JAMAophth: #Semaglutide, taken for diabetes or obesity, was associated with non-arteritic anterior ischemic optic neuropathy (NAION). https://t.co/dZWOZM3e5m https://t.co/0QhrjzeIGS
@PeterDiamandis No possible benefit is worth the risk of losing sight, however small that risk is. https://t.co/VxAM49llbx
@epochhealth https://t.co/5RxWRqgSQE
@MellyMnemosyne People who take GLP1 inhibitors are risking their health for something that can, in most cases, be achieved by dietary and lifestyle changes. No benefit is worth losing eyesight, no matter how low the risk of that happening is. https://t.co/VxAM49llbx https://t.co/0otXSWcgX5
@eberilka @DahiliyeDoktoru https://t.co/4mOAFCBycF
@eigenrobot https://t.co/VEnp8h90ML
RT @ehlJAMA: DO GLP-1 Agonists Really Cause Eye Disease There has been a huge amount of press about a report showing an association betwee…
@Mulsorc @Dr_Alice_Woods Такому интеллектуалу наверное не трудно будет погуглить, кто и как проводит большинство исследований и на чьи бабки. Но я не отговариваю. Пейте на здоровье свой оземпик. Биг фарма никогда раньше людей не колечила, с чего б ей начинать? https://t.co/ZV3eziWhHL
Ophthopedia Update: Comment on: The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Dear Editor, #Ophthalmology #Ophthotwitter #Scicomm
Ophthopedia Update: Reply to Comment on The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: We would like to thank Dr. Hsu, Dr. Lin, and colleagues for their thoughtful commentary on our work evaluating the… #Ophthalmology #Ophthotwitter #Scicomm
眼科領域は引き続き注意深くみてく必要を感じる ほか https://t.co/8SSlx7l0jr https://t.co/4mUJhfZ0P5
Problemas intentinales graves: https://t.co/QC1kS3PU44 Achica el miocardio: https://t.co/o5qYSHQh7V Aumenta el riesgo de neuropatía óptica: https://t.co/MpyZfA8RoE + https://t.co/7lwa4eObe5 Etcetc. Hay mucha propaganda a favor hoy en día, pero banquen unos años.
@jsenior64 @alejoromanmd 1. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. Hathaway JT, Shah MP, Hathaway DB, et al. JAMA Ophthalmology. 2024;142(8):732-739. doi:10.1001/jamaophthalmol.2024.2296.
@SergioAmaya88 @alejoromanmd Ahí está en el trino las referencias. Este es una de ellas. https://t.co/5G3O5a8Yf6
確かに多いな>セマグルチドーNAION https://t.co/aIGIFuTn7Q
@VigilantFox #DoNoHarm https://t.co/Qzrna3xjTh
Prenons garde a ces produits anti-obesité. Des risques accru de perte de la vue (neuropathie optique ischémique antérieure) seraient associés au Sémaglutide. Ces risques sont multipliés par 4 pour les diabétiques et par 7 pour les personnes en surpoids. https://t.co/uK6sPljjNd https://t.co/yWkBCiLL1o
No Thx / American Medical Association Jama Network: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy [Blindness] in Patients Rx'd #Semaglutide. #Wegovy #Ozempic #Zepbound #tirzepatide #glucagonlikepeptide1 #GLP1 #receptor #agonists #Diabetes #WeightLoss #MedSky jamanetwork.com/journals/jam...
Ophthopedia Update: Semaglutide May Increase the Longer-Term Risk of NAION in Patients With Diabetes: A retrospective study reported a slightly greater risk of nonarteritic anterior ischemic optic neuropathy (NAION) in patients with type 2 diabetes who took semaglutide vs… #Ophthalmology #News
Does Ozempic increase the risk of nonarteritic anterior ischemic optic neuropathy (NAION)? A lawsuit recently filed in New Jersey is seeking answers.
@DrPops3 @NateB_Panic https://t.co/LpXbdLI2ve
@cremieuxrecueil For certain auto immune conditions there can be some risks (https://t.co/aNJ7g1vCIA), generally GLP-1 is very safe though
@tchantchea En effet, c’est uniquement destiné aux diabétiques de type deux pas stabilisé. Une étude américaine révèle aussi que les patients sous semaglutide avaient 4 fois plus de risques de devenir aveugles. https://t.co/S226QqCNPH
Here’s the original single-center study on the topic suggesting risk (@DavidHathawayMD @zekavatm @HMSEye @MassEyeAndEar @HarvardChanSPH): @JAMAOphth paper: https://t.co/YHrIkCBYdJ 2/5
More real world cohort data from TriNetX assessing whether and at what time points semaglutide use in people with #T2D is associated with an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) jamanetwork.com/journals/jam...
Study of 3 million patients with diabetes found that use of semaglutide (Ozempic) is linked with a 4X greater risk of nonarteritic anterior ischemic optic neuropathy (NAION) compared with non-GLP-1RAs (empagliflozin, sitagliptin, and glipizide). www.ophthalmologyadvisor.com/news/semaglu...
RT @Elitiker: Am Ende ist man schlank, aber leider blind? Semaglutid steht im Verdacht, das Risiko für die nicht arteriitische anteriore is…
RT @Elitiker: Am Ende ist man schlank, aber leider blind? Semaglutid steht im Verdacht, das Risiko für die nicht arteriitische anteriore is…
RT @Elitiker: Am Ende ist man schlank, aber leider blind? Semaglutid steht im Verdacht, das Risiko für die nicht arteriitische anteriore is…
RT @Elitiker: Am Ende ist man schlank, aber leider blind? Semaglutid steht im Verdacht, das Risiko für die nicht arteriitische anteriore is…
RT @Elitiker: Am Ende ist man schlank, aber leider blind? Semaglutid steht im Verdacht, das Risiko für die nicht arteriitische anteriore is…
Am Ende ist man schlank, aber leider blind? Semaglutid steht im Verdacht, das Risiko für die nicht arteriitische anteriore ischämische Optikus-Neuropathie (NAION) zu erhöhen, je nach Studie um das bis 4-fache. https://t.co/7Ykc3fmO5v https://t.co/eaMgUlZ2ky
@chiragbarjatyaa Genuine question, there have been recent reports of vision loss in a% of people who have consumed semaglutide. Is it still safe to consume for obese people. https://t.co/xJig4dnoVC
Ophthopedia Update: This Issue at a Glance: Using data from a deidentified global electronic medical records database, Chou et al (p. 381) retrospectively investigated whether semaglutide increases the risk of nonarteritic anterior ischemic optic neuropathy… #Ophthalmology #ophthotwitter #eyecare
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | JAMA Ophthalmology- $VKTX VK2735 is to $NVO Ozempic & $LLY Zepbound (not Semaglutide but implicated In papillitis & maculopathy) as Revlimid is to Thalidomide. https://t.co/wr6nBfjX3r
@leanhealth Can also make you blind. https://t.co/LpXbdLI2ve
RT @Nak_Muay_Thai: I told my friends and family to stay away from this stuff…now people are going blind. Thanks big pharma. https://t.co/oW…
@noir_ism 急性膵炎に加えて非動脈炎性虚血性視神経症」(NAION)による失明リスクについてもまだ決着がついていないので適応外使用は怖くてできません 2024/7後ろ向きコホートではNAION発症リスクと関連あり https://t.co/IwpOpvoM61 2024/11後ろ向きコホートでは関連なし https://t.co/7Uo3ur3Due
@Timcast https://t.co/BleGt4Fu5f
@JulieOnX24 @TheRealKingRosa @Timcast https://t.co/BleGt4Fu5f
@bayeslord https://t.co/NGT1tyBv59 https://t.co/Gu6X8rivs4
Semaglutide Blinds most commonly in the Nondiabetic Cohort- cumulative incidence of NAION of 6.7% (95% CI, 3.6%-9.7%) for the semaglutide cohort vs 0.8% (95% CI, 0%-1.8%) for the nonsemaglutide cohort.” 7x - vs 3x in Diabetic cohort. https://t.co/GsADnRH2J3 $NVO
I told my friends and family to stay away from this stuff…now people are going blind. Thanks big pharma. https://t.co/oWPrgXn915
https://t.co/bFDdmSvtKW
RT @TonyFauci2: Risk of NAION in Nondiabetic Wegovy patients Highly Significant -semaglutide vs non–GLP-1 RA cohorts over 36 months was 6.7…
Risk of NAION in Nondiabetic Wegovy patients Highly Significant -semaglutide vs non–GLP-1 RA cohorts over 36 months was 6.7% (95% CI, 3.6%-9.7%) and 0.8% (95% - P < .001). Get a safer drug $NVO > $VKTX https://t.co/wr6nBfkuSZ
@jacobjamesrich @drsimonegold https://t.co/aAdsc7mIfA
@TXtoDCtoCA @drsimonegold Did anyone bother reading it? They weren't all diabetic? https://t.co/aAdsc7mIfA
@QuantPsychiatry Maybe not that fast https://t.co/NoEztAcIND
@AlegonPepe @UHN_Plus Acá el estudio completo. No se pueden tomar medidas ni recomendar o dejar de recomendar por 9 pacientes en millones que lo reciben. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/94FivpNlCd
@UHN_Plus Por si a alguien le interesa envío enlace Saquen sus propias conclusiones https://t.co/1onFZegcEh
RT @TonyFauci2: #JAMA on over 600 cases on NAION in Boston : “Given that semaglutide was first approved to treat T2D but plausible confound…
@Jeroz @makutyre @Simpsons_tweets https://t.co/OngEjoLYY6 However; "future study is required to assess causality." So we're going to have to wait a while I guess.
#JAMA on over 600 cases on NAION in Boston : “Given that semaglutide was first approved to treat T2D but plausible confounding factors were not significant contributors to the risk of NAION” $NVO and now $LLY Rxs implicated - not $VKTX https://t.co/Az3PRUvn08
https://t.co/XTBiu1ybfL
NAION is a rare optic nerve disease that can cause permanent blindness. Once it happens, there’s no reversing it.
En un registro de pacientes con neuropatía isquémica óptica, semaglutide en DM y en obesidad. https://t.co/5G3O5a8Yf6
@HilldurG @ZubyMusic https://t.co/d8hKcTNfuq
@mask_bastard Obviously more to the story, but its the Daily mail. https://t.co/NGf5wVQHJI Also being overweight sucks.
they have known about Ozempic and blindness for some time https://t.co/37v3RNoIuS
they have known about Ozempic and blindness for some time https://t.co/W4ILMOdHTY
@Jackie__Knowsss https://t.co/r2Q4mkZcDG Here’s a study, it’s a rare condition but yeah I also would not risk it lol. I also saw mentioned that diabetes medications in general are linked to vision problems so there’s that.
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/GbC0k5Oz6s
@YoloSwagQtPi @tuck54378 @Timcast Yeah, that's exactly how science works. Clown. Here's another study with similar results. https://t.co/rwQsKgwatY
Non vorrei dire, ma la cosa si sa da luglio 2024 quando fu pubblicato uno studio, durato 6 anni e che coinvolgeva 17mila pazienti, su rischio neuropatia ottica ischemica anteriore non arteritica o NAION https://t.co/lLgs7x4DBy https://t.co/tOCItiwkx0
@Timcast https://t.co/LJP7UdS0TF Studies are still being conducted and the risk benefit ratio is being assessed. The risk of NAION is extremely small generally. The risks of Diabetic Retinopathy, which can also cause blindness, in untreated patients is higher.
@BaronBoehm @Timcast It's unknown what the mechanism is but it could well have more to do with the rapid pace of weight loss rather than the drug itself https://t.co/HnmiOvTUDZ
RT @ehlJAMA: DO GLP-1 Agonists Really Cause Eye Disease There has been a huge amount of press about a report showing an association betwee…
RT @ehlJAMA: DO GLP-1 Agonists Really Cause Eye Disease There has been a huge amount of press about a report showing an association betwee…
RT @OleksandrKashu2: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/CZfqKbbHsC
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/CZfqKbbHsC
@_parasocial Yeah, the retina just doesn’t do well with big swings in blood sugar. And clearly the diabetes and obesity are the bigger issues, this is something that ophthalmologists are looking in to. https://t.co/TDHoR4noo7
@SmithJane007 @Juliesnark1731
@BEisenhart Too late https://t.co/38iMZRjA6e https://t.co/B9XH58ZOi9
@Annanor @bryan_johnson https://t.co/wr6nBfkuSZ
RT @JAMAOphth: Most Viewed @JAMAOphth 2024: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
Most Viewed @JAMAOphth 2024: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
@mtdzen @JanieChuckles @morri_maurizio @DefiantLs Here is (the first) study examining what had been anecdotal association of semaglutide with NAION. Jump to the “limitations” section to read why further study is necessary. https://t.co/SSti3rAHoF
RT @ShineCo2012: @DefiantLs @im_a_Dan Drugs like Ozempic, Wegovy linked to eye condition causing vision loss: https://t.co/DLt7s6tLAi Inves…
@DefiantLs @im_a_Dan Drugs like Ozempic, Wegovy linked to eye condition causing vision loss: https://t.co/DLt7s6tLAi Investigation: https://t.co/6Ronirqn7S https://t.co/cPPPD0q46Y
@DefiantLs https://t.co/znqWyiwaqm
@Techgnostik @BigImpactHumans @DadRetroGamer There is research going on related to this. Don't just blabber some nonsense about no direct proof. It's within the realm of possibilities. https://t.co/BJfWfQ0ziA
https://t.co/yTtYAKjxBr
@tisfortech @BigImpactHumans https://t.co/SKtbWRpHA5
Here is a link to the study. It’s an observational study of over 16K participants. This should be watched carefully. https://t.co/SKtbWRpHA5 https://t.co/Gk4nD7vGMY
@TheKrzysztoff @MargBarAmerica Ozempic has been linked to a higher incidence of NAION. Even though its a rare disorder, it has an alarmingly increased incidence Increased risk of cancer is significant in patients with history of medullary thyroid cancer https://t.co/M2mvMGN0Rv https://t.co/WYhkf0AsmD
RT @gri999999: Kind of a bummer if you are taking this. https://t.co/ub6VrGh8HX
Kind of a bummer if you are taking this. https://t.co/ub6VrGh8HX
◎参考3 Jimena Tatiana Hathaway, Madhura P Shah, David B Hathaway, et al. : Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol 142(8) : 732-739, 2024. DOI: 10.1001/jamaophthalmol.2024.2296 https://t.co/5f061PGGAI
OniX OnPoint newsletter: Semaglutide Associated with Increased Risk of Nonarteritic Anterior Ischemic Optic Neuropathy www.linkedin.com/pulse/semagl... via @LinkedIn
RT @benryanwriter: STUDY: Ozempic tied to rare blinding condition Patients prescribed Ozempic or Wegovy for diabetes or weight loss had a h…
RT @Lily4Lily2: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/6ZyHF5yaU7
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/6ZyHF5yaU7
doi:10.1001/jamaophthalmol.2024.2296
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA Ophthalmology | JAMA Network https://t.co/DVapEtHW7i
@kevinnbass Lookup “semaglutide” and “NAION” (Nonarteritic Anterior Ischemic Optic Neuropathy) and tell me how trustworthy it is… https://t.co/vu8YAsbiSF
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/DqQZnp7v0y
@dr_ukio セマグルチドを処方された患者における非動脈性前虚血性視神経障害のリスク GLP1 糖尿病https://t.co/g5laUdKtqk
New study finds potential link between semaglutide (Ozempic, Wegovy) and increased risk of NAION, especially within the first year of treatment. Important implications for patients with DM and obesity. Read more: https://t.co/umnbtYetrB @JAMAOphth #Ophthalmology
@usmansaeedMD I think ozempic is becoming an outstanding option for diabetic and obese patients. Side effects are part of any drug, I personally found interesting the correlation between ozempic and nonarteritic anterior ischemic optic neuropathy. DOI:10.1001/jamaophthalmol.2024.2296
Journal Club SID Wegovy e Ozempic: Perdere Peso o la Vista? - A cura di Maria Vittoria Cicinelli, Roberto Perilli https://t.co/7uOJM2HmMy
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/ItddZKhOA0
RT @JAMAOphth: Listen to an interview with Joseph F. Rizzo III author of "Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patien…
RT @JAMAOphth: Listen to an interview with Joseph F. Rizzo III author of "Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patien…
Listen to an interview with Joseph F. Rizzo III author of "Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide," and Neil M. Bressler. Find the episode on @AMAEdHub. https://t.co/dRfmZfFKlg
RT @lifebiosciences: #ICYMI, a study published in @JAMAOphth by Dr. Joe Rizzo discusses the potential association between semaglutide and #…
#ICYMI, a study published in @JAMAOphth by Dr. Joe Rizzo discusses the potential association between semaglutide and #NAION. Our #PartialEpigeneticReprogramming platform aims to offer the first potential treatment for this rare eye disease. Read here: https://t.co/LdB49B4xDp. https://t.co/UYo1lXwpJg
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/TVxnuUb8cY
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/5E8epJskrh
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/3q8gWnv498 via @practiceupdate
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/nh6Eg7QBvC
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/UcsJxKvvQZ
Did you know? Ozempic might have a blind spot! Dive into the surprising association between ozempic & NAION at https://t.co/umnbtYdVC3 #ophthalmology #ophthotwitter #ozempic
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/qsMAgW0pjw #glp1 #endocrinology #endotwitter
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA Ophthalmology | JAMA Network https://t.co/tBT6nR98uN
RT @NeuroscienceNew: “Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide” by Joseph Rizzo et al. JA…
RT @kksheld: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA Ophth…
RT @kksheld: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA Ophth…
RT @kksheld: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA Ophth…
RT @kksheld: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA Ophth…
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA Ophthalmology | JAMA Network https://t.co/0EwzUrWnRe
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA Ophthalmology | JAMA Network https://t.co/NdgUJqs6u7
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/PK6OrAFmLl
RT @shashiiyengar: If you are taking Glp1a for wt loss then be sure you have a good health insurance policy with you. You may need it h/t…
RT @shashiiyengar: If you are taking Glp1a for wt loss then be sure you have a good health insurance policy with you. You may need it h/t…
RT @shashiiyengar: If you are taking Glp1a for wt loss then be sure you have a good health insurance policy with you. You may need it h/t…
If you are taking Glp1a for wt loss then be sure you have a good health insurance policy with you. You may need it h/t @arunkumar3112 @dlifein @TheIraSahay
RT @MoHossain: The findings suggest a potential risk of #NAION associated with prescriptions for semaglutide .. Risk of Nonarteritic Ante…
Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide https://t.co/sOlRlh7Fmr
Ozempic / Semaglutide increases risk of disease that causes blindness (nonarteritic anterior ischemic optic neuropathy - NAION) https://t.co/atYDWjOOfD Great stuff "Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide" (Hathaway 2024)
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/lChGgSut2e #Diabetes#weightloss#Ozempic#Wegovy#NAION
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/lChGgSut2e
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/FuvTDOzSWF
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/WKRGUNf59D
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/SUFid2hFcG https://t.co/C41PWvL8vx
RT @MoHossain: The findings suggest a potential risk of #NAION associated with prescriptions for semaglutide .. Risk of Nonarteritic Ante…
RT @DrYukselUrun:
Semaglutide could cause severe vision loss: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA Ophthalmology | JAMA Network https://t.co/9n4CVgkHMx
RT @DrYukselUrun:
RT @DrYukselUrun:
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide potential risk of NAION associated with prescriptions for semaglutide, but future study is required to assess causality. https://t.co/lv3V62d4NS
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA Ophthalmology | JAMA Network https://t.co/KcaE136Yxu
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide -reduced blood flow without true inflammation of the blood vessels of the eye https://t.co/cIl3JRMOj1 https://t.co/7UrNL2crkE
RT @JohnNosta: KEY READ!
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA Ophthalmology | JAMA Network https://t.co/HnLMt3z6lv
а вот и первые потенциальные проблемы от Оземпика подъехали: у пациентов с диабетом и ожирением, принимавших семаглутид, нашли повышеный шанс развития ишимической оптической нейропатии исследование наблюдательное, выводов о связи одного со вторым пока нет https://t.co/WkGMMPVLtF
RT @JohnNosta: KEY READ!
RT @37phoenix: セマグルチドはGLP-1作動薬以外の糖尿病薬と比較して非動脈炎性前部虚血性視神経症のリスク上昇と関連するかもしれない. JAMA Ophtalmol. PMID: 38958939. https://t.co/x1V5Oi2HP9
セマグルチドはGLP-1作動薬以外の糖尿病薬と比較して非動脈炎性前部虚血性視神経症のリスク上昇と関連するかもしれない. JAMA Ophtalmol. PMID: 38958939. https://t.co/x1V5Oi2HP9
RT @JohnNosta:
RT @JohnNosta: KEY READ!
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/s9OaekydOc
RT @NeuroscienceNew: “Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide” by Joseph Rizzo et al. JA…
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA Ophthalmology | JAMA Network https://t.co/SULADbll6a
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. https://t.co/JCUdbbiRzu
「減肥神針」恐致失明?注射 Ozempic、Wegovy 可能增加罹患 NAION 風險,諾和諾德嚴正看待研究報告。 #減肥神針 #失明 #副作用 https://t.co/qCtZwXdZq9
Blind or Fat? New Study Reveals Ozempic, Wegovy Linked To 'Potentially Blinding Eye Condition' Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/rc0TFThcux
RT @benryanwriter: STUDY: Ozempic tied to rare blinding condition Patients prescribed Ozempic or Wegovy for diabetes or weight loss had a h…
RT @caminalm: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/Co8lP2qxuK
Riesgo de neuropatía óptica isquémica anterior no arterítica en pacientes a los que se les prescribe semaglutida JAMA Ophthalmol. Publicado en línea el 3 de julio de 2024. doi:10.1001/jamaophthalmol.2024.2296
Patients taking semaglutide (Oxempic/ Wegovy) should be aware of its risks! NAION reported… https://t.co/0CG056Yq1C
RT @Ryu04196650Ryu: GLP-1受容体作動薬Semaglutideと非動脈炎性前部虚血性視神経症NAIONのリスクに関する論文 @JAMAOphth (2024) 因果関係はわかりませんが注視したいですね。 Risk of Nonarteritic Anter…
GLP-1受容体作動薬Semaglutideと非動脈炎性前部虚血性視神経症NAIONのリスクに関する論文 @JAMAOphth (2024) 因果関係はわかりませんが注視したいですね。 Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/uzXEYHr0aG
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/Co8lP2qxuK
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/2l7nSWRNGj
حذاري #أوزيمبك قد يسبب #العمى لدى مرضى #السكر و #السمنة #semaglutide Brand names #Ozempic, #Wegovy, #Rybelsus Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/2l7nSWRNGj
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/ZmFGEAxWv0
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/ovUX3Rxwnf
RT @docwas: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA incide…
RT @docwas: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA incide…
RT @docwas: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA incide…
まーたリリーの株が上がるのか Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/e8qeU3XbxF
RT @NeuroscienceNew: “Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide” by Joseph Rizzo et al. JA…
RT @yianniszacharia: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide @SBakerMD @Mangan150 @ProfT…
【JAMA Ophthalmol.July 3, 2024】 Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/NjkN86hwTm
Hey @DGlaucomflecken when you get back on this side of the pond will you please weigh in on this? Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/YPHlbFDlRA
Hey @DGlaucomflecken when you get back on this side of the pond will you please weigh in on this? Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/YPHlbFDlRA
RT @benryanwriter: STUDY: Ozempic tied to rare blinding condition Patients prescribed Ozempic or Wegovy for diabetes or weight loss had a h…
RT @benryanwriter: STUDY: Ozempic tied to rare blinding condition Patients prescribed Ozempic or Wegovy for diabetes or weight loss had a h…
RT @docwas: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA incide…
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA incidental observation study or a concern? Will need an RCT @kamleshkhunti @AskDrShashank @docanoopmisra https://t.co/c6rFG4y0e2
RT @benryanwriter: STUDY: Ozempic tied to rare blinding condition Patients prescribed Ozempic or Wegovy for diabetes or weight loss had a h…
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA Ophthalmology | JAMA Network
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide @SBakerMD @Mangan150 @ProfTimNoakes @DrPaulMason @TuckerGoodrich https://t.co/r0HCZA0ZZM
RT @JohnNosta: KEY READ!
RT @MoHossain: The findings suggest a potential risk of #NAION associated with prescriptions for semaglutide .. Risk of Nonarteritic Ante…
RT @JohnNosta:
“Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide” by Joseph Rizzo et al. JAMA Opthalmology https://t.co/MuUSyqlr5g 3/3
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | Diabetic Retinopathy | JAMA Ophthalmology | JAMA Network https://t.co/d08FImgI7Q
I'll be curious to hear @hubermanlab thoughts on this one... Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.https://t.co/hRZAMGiH3s
I'll be curious to hear @hubermanlab thoughts on this one... Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.https://t.co/hRZAMGiH3s
RT @JohnNosta: KEY READ!
RT @JohnNosta: KEY READ!
KEY READ!
RT @benryanwriter: STUDY: Ozempic tied to rare blinding condition Patients prescribed Ozempic or Wegovy for diabetes or weight loss had a h…
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/SCfn13ksRY
The findings suggest a potential risk of #NAION associated with prescriptions for semaglutide .. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide | @JAMA_current https://t.co/3y9phee1mC #blindness #sugar #glp1 #GLP-1 #diabetes https://t.co/BZk9PSVgB1 https://t.co/pW3zUDwDLb
RT @benryanwriter: STUDY: Ozempic tied to rare blinding condition Patients prescribed Ozempic or Wegovy for diabetes or weight loss had a h…
RT @benryanwriter: STUDY: Ozempic tied to rare blinding condition Patients prescribed Ozempic or Wegovy for diabetes or weight loss had a h…
RT @benryanwriter: STUDY: Ozempic tied to rare blinding condition Patients prescribed Ozempic or Wegovy for diabetes or weight loss had a h…
RT @benryanwriter: STUDY: Ozempic tied to rare blinding condition Patients prescribed Ozempic or Wegovy for diabetes or weight loss had a h…
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide https://t.co/x07irnrUL5
RT @benryanwriter: STUDY: Ozempic tied to rare blinding condition Patients prescribed Ozempic or Wegovy for diabetes or weight loss had a h…
STUDY: Ozempic tied to rare blinding condition Patients prescribed Ozempic or Wegovy for diabetes or weight loss had a higher risk of having a potentially blinding eye condition called NAION than similar patients not on the drugs. https://t.co/PqhNnIOQ2i https://t.co/1GaZAFfIO0 https://t.co/uzTTuQTHMS
E
FD
C
T
JM
TN
SB
TL
AH
O
Mإ
BS
M
G
GJ
C
A
T
BH